一年来血防药物科研方面取得了较大的成绩,双萘羟酸付品红,经过较系统的药理、毒理的研究和对1,413例的临床观察,证明该药疗效较高,付作用较轻,适应症较广,可以用来治疗伴有夹杂症和晚期血吸虫病患者,已鉴定投产推广使用。硝硫氰胺(7505)经7万多例的临床观察和药理、毒理、生产工艺等方面深入研究, A year of blood drug research has made greater achievements, the double naphthalene acid Fuguidong, after more systematic pharmacology and toxicology studies and clinical observation of 1,413 cases, the drug proved to be more effective, pay less , A wide range of indications, can be used to treat patients with complications and advanced schistosomiasis, has been identified to promote the use of. Nitrocyanatine (7505) by more than 70,000 cases of clinical observation and pharmacology, toxicology, production processes and other aspects of in-depth study,